MediPines
Private Company
Total funding raised: $10M
Overview
MediPines, founded in 2014, is a commercial-stage diagnostics company addressing a critical gap in emergency and acute care: the rapid, non-invasive assessment of respiratory impairment. Its AGM100® device delivers actionable data on oxygenation, ventilation, and gas exchange in under two minutes, supporting faster clinical decisions and potentially reducing unnecessary tests and admissions. The company has achieved significant commercial milestones, including a dedicated CPT reimbursement code, positioning it for growth in the expansive respiratory diagnostics market.
Technology Platform
Non-invasive point-of-care device (AGM100®) that uses advanced sensors and computational algorithms to measure oxygenation, ventilation, and gas exchange efficiency in a single breathing session, providing data comparable to invasive arterial blood gas analysis.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
MediPines competes with the entrenched standard of care, which includes serial testing with pulse oximetry, arterial blood gas (ABG) analyzers, chest X-rays, and CT scans. It also faces competition from other non-invasive monitoring devices and multi-parameter vital signs monitors. Its key differentiation is the specific, non-invasive quantification of gas exchange impairment—a parameter traditionally requiring invasive ABG—delivered rapidly at the point of care.